What is Orgenesis?
Orgenesis is dedicated to unlocking the full potential of cell and gene therapies (CGTs) by making them affordable and accessible at the point of care. Its proprietary POCare Platform integrates a pipeline of licensed therapeutics with automated production systems and a collaborative network. This integrated approach aims to accelerate the delivery of CGTs to a broad patient population, reducing costs through efficient, decentralized manufacturing. The POCare Network fosters collaboration among patients, clinicians, research institutions, and industry partners to streamline clinical development and regulatory pathways for these advanced therapies.
How much funding has Orgenesis raised?
Orgenesis has raised a total of $55M across 2 funding rounds:
Unspecified
$50M
Private Equity
$5M
Unspecified (2022): $50M with participation from Metalmark Capital
Private Equity (2023): $5M led by Metalmark Capital Partners
Key Investors in Orgenesis
Metalmark Capital
Metalmark Capital is a growth equity investment firm that focuses on founder-owned businesses in the middle market, aiming to build long-term value through active partnerships. They primarily invest in privately held companies with significant strategic footprints and growth objectives in North America.
Metalmark Capital Partners
Metalmark Capital Partners is an investment entity associated with Metalmark Capital, likely involved in providing growth capital for companies with substantial strategic footprints and expansion plans.
What's next for Orgenesis?
The recent major strategic investment signals Orgenesis's readiness to accelerate its growth and expand its market reach. This capital infusion is expected to bolster the development and deployment of its POCare Platform, potentially enabling wider adoption of its decentralized CGT production model. The company's focus on harmonized clinical development and scalable manufacturing positions it to address significant unmet needs in the advanced therapeutics sector, paving the way for future enterprise-level expansion and strategic partnerships.
See full Orgenesis company page
